Geron | GERN - Ordinary Share Capital


Geron reported $636.92M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 555.2M
Cash and Equivalent USD 79.6M
Cost of Sales USD 1.19M
Current Assets USD 505.6M
Current Liabilities USD 64.28M
Debt USD 121.84M
EBIT USD -12.45M
EBITDA USD -7.55M
Employees 229
EPS Earnings Per Share USD -0.02
Equity Capital and Reserves USD 259.53M
Gross Profit on Sales USD 47.85M
Interest Expense on Debt USD 8.52M
Interest Income USD 4.66M
Loan Capital USD 118.99M
Market Capitalization USD 846.3M
Net Income USD -16.38M
Operating Expenses USD 61.49M
Operating Profit USD -12.45M
Ordinary Share Capital USD 636.92M
Pre-Tax Profit USD -16.38M
Sales Revenues USD 49M
Selling and Administration Expenses USD 38.56M
Stock USD 69.13M
Trade Creditors USD 8.23M
Trade Debtors USD 39.36M

Ordinary Share Capital Change Date
Amgen USD 538M 33.04B Jun/2025
Bio Techne USD 156.76M 155.19M Jun/2025
Cassava Sciences USD 48.31M 48.26M Jun/2025
Cytokinetics USD 119.6M 119.48M Jun/2025
Exelixis USD 270.13M 269.86M Jul/2025
Genmab DKK 10M 56M Mar/2025
Geron USD 636.92M 636.28M Jun/2025
Gilead Sciences USD 1.24B 3M Jun/2025
Incyte USD 194.12M 193.93M Jun/2025
MacroGenics USD 63.21M 62.58M Jun/2025
Novartis USD 793M 0 Dec/2024